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The goal of this review is to summarize the rationale for and feasibility of hippocampal sparing techniques
during brain irradiation. Radiotherapy is the most effective non-surgical treatment of brain tumors and with the
improvement in overall survival for these patients over the last few decades, there is an effort to minimize potential
adverse effects leading to possible worsening in quality of life, especially worsening of neurocognitive function.
The hippocampus and associated limbic system have long been known to be important in memory formation and
pre-clinical models show loss of hippocampal stem cells with radiation as well as changes in architecture and
function of mature neurons. Cognitive outcomes in clinical studies are beginning to provide evidence of cognitive
effects associated with hippocampal dose and the cognitive benefits of hippocampal sparing. Numerous feasibility
planning studies support the feasibility of using modern radiotherapy systems for hippocampal sparing during brain
irradiation. Although results of the ongoing phase II and phase III studies are needed to confirm the benefit of
hippocampal sparing brain radiotherapy on neurocognitive function, it is now technically and dosimetrically feasible
to create hippocampal sparing treatment plans with appropriate irradiation of target volumes. The purpose of this
review is to provide a brief overview of studies that provide a rationale for hippocampal avoidance and provide
summary of published feasibility studies in order to help clinicians prepare for clinical usage of these complex
and challenging techniques.
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Both primary and secondary brain tumors (BT) represent a
significant public health problem. An increasing incidence
in primary brain tumors (PBT) as well as brain metastasis
(BM) has been documented over recent years. In 2014,
more than 24,000 new PBT are estimated to be diagnosed
in the United States [1]. Moreover, about 1,4 million new
solid tumor cases of all histological origin are diagnosed
each year in the United States and approximately 30% of* Correspondence: tomas.kazda@mou.cz
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unless otherwise stated.them develop BM [1]. Therefore, management of BT is an
increasingly important component of cancer therapy [2].
Radiotherapy is an important modality in the treatment
of BT. Radiotherapy remains the standard treatment for
vast majority of high-grade or malignant brain tumors and
plays an integral role in treatment of many low-grade and
benign primary brain tumors. However, concerns regard-
ing neurocognitive toxicity after radiotherapy in patients
with benign or low-grade tumors make the timing of
treatment controversial [3].
Historically, radiotherapy was also a mainstay of treat-
ment for BM. With improved survival and increased
awareness of the cognitive effects of WBRT, the role of
WBRT in BM has come under question [4]. Because of
these concerns there has been a trend towards increased
reliance on focal treatments such surgery and stereotactictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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control is associated with improved survival and preserved
neurocognitive domains with exception of memory func-
tion, especially recall and delayed recall [6]. Thus, under-
standing the risk of brain tumor recurrence at distant sites
of brain is important in counseling patients regarding the
risks and benefits of WBRT. Patients with single BM and
no extracranial metastases are at low risk for in-brain re-
currence and omitting early WBRT because of the risk of
intermediate and late adverse effects (AE) can be safely
done as long as the patient commits to regular imaging
[7]. Conversely, patients with progressive systemic disease
are at a higher risk for distant brain failure and likely
benefit from the addition of WBRT despite possible late
complications [8].
For most malignant adult PBT and BM, radiotherapy
prolongs survival but is rarely curative. Thus, emphasis
on minimizing the AE of treatment is becoming one of
the most important factors in the treatment. Recently,
more attention has been paid to symptom related out-
comes of care, especially to neurocognitive function (NCF)
and quality of life (QoL) [9-11]. With improvements in
radiotherapy systems technology, it is now possible to
modify treatment plans to selectively spare structures that
may contribute to decreased QoL and NCF. In order to
achieve this aim, it is important to determine appro-
priate end-points primarily in relation to the ongoing
randomized clinical trials as resources for future treatment
guidelines [12].
Decline in NCF as an iatrogenic side effect of brain
irradiation is well-known [13]. The mechanism of radi-
ation injury is complex and multi-factorial. In the past,
cognitive decline after radiotherapy was believed to be a
late effect of treatment mediated through microvascular
changes and neuroglial loss. However, there is increasing
evidence for acute and subacute cognitive changes after
radiotherapy that appear to be mediated through the
neurogenic zones including the hippocampus. Preclinical
evidence supports the concept of hippocampal radiation
injury as a mediator of subsequent AE, most notably in
memory-related domains of neurocognition [14]. Retro-
spective clinical reports as well as early results of pro-
spective trials support the role of hippocampus in early
changes in cognitive function after radiotherapy [11]. The
purpose of this review is to provide a brief overview of
studies that provide a rationale for hippocampal avoidance
(HA) and provide summary of published feasibility studies
in order to help clinicians prepare for clinical usage of
these complex and challenging techniques.
Hippocampus and radiation injury
The hippocampus is a paired brain structure, located
in the ventromedial part of the temporal lobes, laying
lateral to the temporal horn of the lateral ventricle. Thehippocampus is composed of the dentate gyrus and the
cornu ammonis regions and belongs to the limbic system.
Its main role in brain function is cooperation in learning,
consolidation and retrieval of information and it is also es-
sential for formation of new memories [15]. Bilateral and
unilateral radiation injury of the hippocampus is known
to alter learning and memory formation [16]. Complete
pathophysiologic explanation of all these processes is still
lacking; nevertheless, the role of neurogenesis seems to be
one of the most compelling [17].
Mitotically active neural stem cells (NSCs) are located
in different parts of brain, namely in the subependymal
zone and in the subgranular zone of the dentate gyrus,
wherefrom they migrate into the granular cell layer of
hippocampus [18]. The hippocampal subgranular zone is
a critical neurologic center for learning and memory [19].
NSCs have typical features of the stem cells. They are cap-
able of both self-renewal and generating new differenti-
ated cells [20]. Neurogenesis is a complicated process with
integration of many regulatory cells as astrocytes or endo-
thelial cells with coordinate evolution of neural precursor
cells together with each other in a specific neurogenic
microenvironment called “niche” [21,22].
Multiple preclinical studies support the hypothesis of
hippocampus-mediated cognitive dysfunction [23-30]. In
vivo animal studies demonstrate sensitivity of these NSCs
to ionizing radiation. Apoptosis of NSCs after ionizing
radiation was first described in the subependymal zone in
the young adult rat. After single x-ray doses of 5 or 30 Gy,
apoptosis peaked 6 hours after irradiation [23]. Several
years later, postradiation apoptosis was observed also in
the rats’ dentate gyrus after exposure to single 10 Gy dose
[24]. Decline in neurogenesis was associated with cog-
nitive impairment in rodent models for both single and
fractionated brain irradiation [14,25]. Mizumatsu et al.
irradiated the whole brain of experimental mice with vari-
ous single doses and used immunohistochemical staining
methods for detection of apoptosis as well as numbers of
proliferating cells and immature neurons in the subgranular
zone of the hippocampal dentate gyrus. Dose-dependent
apoptosis was observed and peaked 12 hours after irra-
diation followed by subsequent reduction in amount of
proliferating cells in subgranular zone [27]. Changes in
neurogenesis were associated with an inflammatory re-
sponse as validated by detection of activated microglia
cells [29]. Moreover, administration of anti-inflammatory
agents such as ramipril and indomethacin can mitigate
radiation-induced cognitive impairment in rodents sug-
gesting the inflammatory response is important in mediat-
ing the effects of radiotherapy [30].
However, these and other mechanisms of radiation effects
on neurogenesis do not completely describe the radiobiol-
ogy of the hippocampus [31]. More recent in vitro and
in vivo research reveals other important radiation induced
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[32]. Investigators at University of California at Irvine, CA,
USA have optimized a SYBR green based assay to study the
effects of low dose RT before changes are visible radio-
graphically. Even a dose of 2 Gy delivered to human NSCs
leads to decreased numbers of cells undergoing neuronal
differentiation after irradiation [33]. Additional work from
the same group suggests the mechanism of radiation-in-
duced inhibition of neurogenesis may be mediated through
oxidative stress [34].
Although significant pre-clinical data supports a de-
crease in NSC number and function after radiotherapy,
changes in neuronal architecture, as recently described by
Parihar and Limoli in measurements of micromorpho-
metric parameters in mice following cranial irradiation by
1 and 10 Gy, may also be important in mediating the
effects of radiotherapy [35]. Dose-dependent reduction of
dendritic branching, length and area were described as
well as the reduction of immature filopodia as compared
with mature spine morphology of dendritic segments.
These postradiation changes correlated with alterations in
synaptic protein production that were noted up to 1 month
after brain irradiation [35]. These types of changes are
likely to be equally important as disruption of neurogen-
esis in eliciting cognitive decline after radiotherapy.
Recent studies provide dose–response data and estima-
tion of clonogenic survival fraction of human NSCs after
brain irradiation. This data is important from a radiation
oncology point of view primarily for determination of per-
tinent treatment planning recommended dose constraints.
In QUANTEC analysis, the normal brain α/β value
has been established to be 2.9 [36]. For the hippocampal
region, most authors use the α/β ratio in range from 2
to 3 [37]. However, other authors work with the α/β value
for NSCs compartments equal to 10 [38,39] using a
general value established for stem cells [40]. Some authors
use α/β ratio 10 for the true hippocampus and an α/β
value 2 for the whole hippocampus planning-at-risk vol-
ume illustrating the lack of consensus regarding the opti-
mal model of radiation sensitivity. However, preclinical
evidence suggests doses as low as 2 Gy to result in apop-
tosis of neurogenic stem cells supporting a no-shoulder
dose-response [29,33]. Several other studies have mea-
sured altered survival and proliferation using a range of
metabolic and SYBR green based assays. These studies
revealed that doses of as low as 2 Gy reduced survival by
over 50% [33]. Thus, accumulating preclinical data indi-
cate that neurocognitive dysfunction manifests at much
lower doses (<10 Gy) than previously expected [34].
Clinical evidence for hippocampal sparing
In addition to preclinical evidence, retrospective clinical
reports also suggest the hippocampal region may play
a role in NCF decline after radiotherapy. Children withbrain tumors treated on prospective clinical trials that
included planned neurocognitive assessments were eva-
luated with neurocognitive studies up to 5 years after
radiotherapy. Mean doses of 45 Gy or higher to the left
temporal lobes were associated with significant declines in
longitudinal IQ [41,42]. The relationship between hippo-
campal dose level and the risk of subsequent NCF impair-
ment was described in the group of patients with adult
low-grade gliomas; NCF was assessed at the baseline and
at 18 months follow-up for conventionally treated patients.
Biologically equivalent dose greater than 7.3 Gy (equivalent
dose in 2-Gy fractions) applied to 40% of hippocampal
volume was associated with long-term NCF impairment,
especially in list-learning delayed recall [43]. Recently, re-
sults of the first prospective phase II study (RTOG 0933)
of HA in BM patients suggest a reduction in risk of cogni-
tive dysfunction with HA [11]. Primary cognitive outcome
was delayed recall at 4 months as measured by the
Hopkins Verbal Learning Test for patients with WBRT
comparing with those with HA WBRT. Results were com-
pared to historical control group. Only 7% of patients
experienced decline in memory compared to 30% of
patients in the historical cohort (p = 0.0003). QoL was
evaluated as well and was preserved up to 6 months
follow-up. Based on these results, RTOG is planning a
phase III randomized trial of prophylactic cranial irradi-
ation with or without hippocampal sparing for small cell
lung cancer patients (RTOG 1317).
Hippocampus-sparing: feasibility studies
Although evidence is mounting in regards to the import-
ance of the hippocampus in mediating cognitive changes
after radiotherapy, it has only been with recent techno-
logic advances that the feasibility of a meaningful reduc-
tion in hippocampal dose while maintaining acceptable
tumor control probability has been established. Below
we review the feasibility studies evaluating HA for PBT
and BM (Figure 1).
Primary brain tumors: HA feasibility studies
Complex intensity modulated radiotherapy (IMRT) plans
were developed to evaluate the feasibility of sparing con-
tralateral and bilateral hippocampi in glioma patients
[38]. In “sparing” plans for the hemispheric HGG cases,
it was possible to reduce the mean physical dose to the
contralateral hippocampus planning-at-risk volume by
56.8% compared to standard treatment plan prepared
without prospective sparing of the hippocampus (15.8 Gy
vs. 36.6 Gy). In addition, more central location of PBT en-
ables sparing of both hippocampi as documented by mean
physical dose reduction by more than a third (16.8 Gy in
sparing vs. 25.6 Gy in standard plan) [38]. Based on
previous preclinical data, even low doses can result in
NSCs apoptosis, but assuming that hippocampus is
Figure 1 Overview of recently published radiotherapy planning studies dealing with hippocampal avoidance. Only studies with more
than 9 patients included [44].
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hippocampal dose may reduce NCF impairment even
if no unequivocal cut-off dose threshold is known.
Unfortunately, reported dose reduction is related to hip-
pocampal planning-at-risk volumes, which were created
by 3 mm expansion of hippocampi, so it is not possible to
compare these results with other published studies.
PBT are frequent diagnosis in children in whom minimi-
zation of subsequent late AE is even more important. In a
evaluating HA in pediatric gliomas, the NSCs compart-
ments, the limbic circuit and the whole hippocampus
were recognized as organ at risk (OARs) and included in
experimental treatment plans [45]. For each RT plan the
biological equivalent doses were calculated providing
more radiobiologically exact comparison of doses in OARs.
In all cases (10 different PBT), experimental plans signifi-
cantly reduce both mean physical dose (by 56.0%) and
mean biological equivalent doses (by 52.1%) delivered to
the study OARs in comparison to plans without any effort
to spare these structures. As might be expected, greatest
hippocampal sparing was seen in hemispheric gliomas
whereas worse results were observed for diffuse tumors
where whole ventricular RT was indicated.
Brain metastases: HA feasibility studies
Many planning studies have shown the dosimetric feasibil-
ity of HA WBRT using different radiotherapy systems as
linear accelerator (LINAC) based IMRT, helical tomother-
apy or volumetric modulated arc therapy (VMAT). In
addition, HA brain irradiation is also possible using Elekta
IMRT step and shoot systems [46].
The pioneer study was performed in 2007 by Gutiérrez
et al., who tested feasibility of HA WBRT with simul-
taneous integrated boost (SIB) to BM in experimentalradiotherapy plans using helical tomotherapy [47]. Re-
gardless a different setting of treatment plans (pitch and
field width), they described no significant difference in
hippocampal doses. Authors concluded that it is possible
to create combined plans with homogeneous whole brain
dose distribution equivalent to conventional WBRT, while
conformal HA and radiosurgically equivalent dose boost-
ing to individual metastases.
Mean dose guidelines for HA WBRT were first pub-
lished by Gondi [37]. HA plans were compared with
standard WBRT ones where a homogenous dose 30 Gy
was applied to the whole brain including hippocampus.
For HA plans, the median hippocampal dose was achieved
5.5 Gy (Dmax 12.8 Gy) and 7.8 Gy (Dmax 15.3 Gy) for hel-
ical tomotherapy and LINAC based RT, respectively.
These dose reductions have been considered a reference
for other subsequent planning studies.
Because of higher availability of stereotactic systems,
recent trends are to combine WBRT with stereotactic
boosting to BM and thus improve local control. Also in
this sequential concept, it is possible to spare hippocam-
pus in both parts of treatment: HA WBRTand subsequent
HA SRS boost. Moreover, using IMRT, it is possible to
integrate boosting into the first WBRT part in concept of
SIB. Comparing this approach with classical sequential
concept (WBRT + stereotactic radiotherapy), the SIB is
more effective in lowering doses to the hippocampus for
patients with up to 8 metastases [48].
Although multiple techniques allow HA WBRT, treat-
ment time can vary significantly depending on the tech-
nique. Using VMAT for HA WBRT with SIB for melanoma
brain metastases, the average beam-on time was achieved
3.6 min while abide the RTOG 0933 feasibility DV con-
straints [49]. Arc based delivery times are generally faster
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than classical IMRT techniques as discussed in other
one planning study focused on HA WBRT published last
year [46,50].
Similarly as for BM treatment, HA WBRT technique
can be used for prophylactic cranial irradiation (PCI)
where are NCF preserving approaches even more justi-
fied. Comparisons of limbic sparing experimental plans
were conducted in 11 patients indicated for WBRT and
for PCI. Similar reduction of hippocampal biological
equivalent doses was achieved for both of these clinical
situations [51,52]. These results are not surprising con-
sidering the fact, that PCI differ from WBRT only in terms
of fractionation and that the standard radiotherapy tech-
nique is similar.
Comparison of treatment planning results with other
studies is summarized in Table 1.
How to spare hippocampus
Because of hippocampal anatomic shape and central
brain location, it can be a challenge to create appropriate
HA treatment plan for irradiation of both PBT and BM.
Nevertheless, modern IMRT techniques such as helical
tomotherapy or VMAT are able to achieve HA with ac-
ceptable target volume coverage and dose homogeneity.
Although a variety of treatment techniques are available
for HA WBRT, the ability to achieve OAR dose goals
varies by technique. In general, helical tomotherapy of-
fered significantly better HA compared to LINAC based
IMRT in terms of the mean normalized tissue dose, asTable 1 Hippocampal dose-volume constraints and achieved
Author, year Clinical
situation
RT system No. Fractionation
Gutierrez, 2007 [47] WBRT HT 10 15 × 2.15 Gy
Gondi, 2010 [37] WBRT HT 5 10 × 3.0 Gy
LINAC
Hsu, 2010 [50] WBRT + SIB LINAC 10 15 × 2.15 Gy
(SIB á 4.2 Gy)
Marsh, 2010 [51] PCI HT 11 15 × 2.0 Gy
WBRT 11 14 × 2.5 Gy
Marsh, 2010 [52] PCI HT 10 15 × 2.0 Gy
WBRT 10 14 × 2.5 Gy
Van Kesteren, 2012 [39] WBRT LINAC 3D-CRT 10 12 × 2.5 Gy
Nevelsky, 2013 [46] WBRT LINAC IMRT 10 10 × 3.0 Gy
Awad, 2013 [49] WBRT + SIB VMAT RA 30 5-15fx
Prokic, 2013 [48] WBRT + SIB VMAT RA 10 12 × 2.5 Gy
BM 12 × 4.25
WBRT + FSRT VMAT RA 10 12 × 2.5 Gy +
FSRT 2 × 9 Gy
3D-CRT: three dimensional conformal radiotherapy; RA: Rapid Arc; HT: helical tomot
Dmean: mean dose; D100%: dose in 100% of volume; D2%: dose in 2% of volume; Dmewell as the median and maximal hippocampal dose.
However, despite different technical capabilities of men-
tioned radiotherapy systems, it can be concluded, that
using either helical tomotherapy or LINAC based IMRT
is sufficient for sparing not only traditional OARs but
also the hippocampus [37]. An effort to minimize hippo-
campal dose must not lead to irradiation of other brain
OARs. This is important especially for gliomas treated
by overall higher doses compared with treatment of BM.
In addition, dose constraints are expected to be differ-
ent for HA WBRT and HA PBRT. For BM, it is possible
to sufficiently spare both hippocampi, and dose-volume
constraints used in representative HA WBRT planning
studies were summarized in Table 1. On the other hand,
for HA PBRT, especially in the treatment of hemispheric
gliomas, ipsilateral hippocampus is often included in
target volumes (and considering much larger doses com-
pared with WBRT). Thus, it is not possible to achieve
appropriate dose reduction for ipsilateral hippocampus
and only contralateral hippocampus could be considered
as OAR. As an example, for HGG the following con-
straints criteria have been proposed: 0% of the hippocam-
pal volume cannot receive more than 8 Gy in the first
phase of treatment (up to 46 Gy) and no more than 4 Gy
in the final phase (next 14 Gy to the target volume) [38].
Contouring of target volumes is, as a potential source
for systematic error, one of the most important parts of
whole radiotherapy planning process. Structure contour-
ing for radiotherapy purpose is sometimes slightly differ-




Dmax Dmax Dmean Dmedian
6 Gy - 5.86 Gy2 5.34 Gy2 2
6 Gy 3 Gy≤ 20% 12.8 Gy - 5.5 Gy 2
11 Gy 9 Gy≤ 40% 15.3 Gy 7.8 Gy 2
- Dmean < 6 Gy2 - 5.23 Gy2 - 2
15 Gy - 12.5 Gy - -
15 Gy 14.3 Gy
- 11.5 Gy - -
- - - 11.8 Gy - -
13.5 Gy 6Gy - 10
16 Gy D100% < 9 Gy 14.35 Gy - - -
- 32.2 Gy 20.4 Gy 21.9 Gy -
- 12.33 Gy (D2%) 7.55 Gy 7.15 Gy H 2 BM 10
- 15.82 Gy (D2%) 9.8 Gy 9.34 Gy H 2 BM 10
herapy; FSRT: fractionated stereotactic radiotherapy; Dmax: maximal dose;
dian: median dose; H: hippocampus.
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important especially in basic neurological research [53]
as well as in research dealing with diseases connected to
hippocampal impairment [54]. On the other hand, only
some HA radiotherapy feasibility planning studies defined
in detail the process of contouring, almost exclusively with
reference to the Radiation Therapy Oncology Group on-
line contouring atlas [55]. Authors of this atlas do not
contour the entire hippocampus, but are focusing mostly
on the subgranular zone as a place of NSCs occurrence.
This approach is suggested as a standard for HA WBRT.
On the other hand, for HA PBRT, where only the contra-
lateral hippocampus is often spared, it is possible to
contour the whole hippocampus irrespective of its NSCs
rich part according to a radiation oncologist’s guide to
contouring the hippocampus proposed by Chera et al.
[56]. Moreover, considering an attempt to spare NCF
during brain irradiation, some studies defined OARs even
more comprehensively including the whole limbic circuit
(whole hippocampus; the rest of limbic circuit comprising
the amygdalar complex, the fornix, the cingulum, the
cingulated gyrus, and the mammillary bodies) [38,51].
Physician’s requirements expressed in terms of dose-
volume constraints are best achievable using inverse
planning, which enables to set different priority points
to different OARs and target volumes and thus it is
possible to find compromise in dose coverage for all im-
portant treatment structures. As an example, in Table 1
were described parameters for both helical tomotherapy
and LINAC based IMRT as presented in a seminal plan-
ning study [37]. These set of dose-volume constraints
have been used in RTOG 0933 study, a first HA WBRT
clinical trial which results were mentioned above [11].
Although methodology of the study enables differences
in radiotherapy systems for preparation of a particular
treatment plan, plans have to meet the required dosi-
metric constraints prior to approval for clinical use.Table 2 Acceptable and unacceptable variations from per pro
trial [11]
Treatment component Parameter Per protocol
MRI/CT Fusion and Contouring MRI-CT fusion No correction
fusion reques
Hippocampal Contouring ≤ 2 mm devia
the Hausdorff
HA WBRT IMRT Planning PTV D2% ≤ 37.5 Gy
D98%≥ 25 Gy
Hippocampus D100% ≤ 9 Gy
Dmax≤ 16Gy
OARs constraints Optic nerves and chiasm Dmax≤ 37.5 G
Unscheduled break days - 0 break days
*according to comparison with contours prepared by co-principal investigators.
PTV: planning target volume; D2%: dose in 2% of volume; D98%: dose in 98% of volume
30 Gy.Table 2 presents acceptable and unacceptable variations
from “per protocol planning” for including particular IMRT
treatment plan into RTOG 0933 trial. In our HA planning
study, we compare different Arc radiotherapy techniques in
order to achieve mentioned constraints. In the setting of
non-coplanar beams arrangement, we have observed even
higher hippocampal preservation compared to classical
coplanar irradiation (not published data) (Figure 2).
In addition to the recent sophisticated methods enabling
HA during brain irradiation, a simpler technique using
two opposing laterolateral fields with central leaf shielding
for appropriate HA has also been discussed [39]. The
simplicity of this technique could enable radiotherapy
departments that are not equipped with the latest technol-
ogy to still offer HA radiotherapy. This technique is sim-
ple reproducible, as demonstrated by one experimental
plan from our department (Figure 3).
Controversies
There are several medical and ethical controversies espe-
cially about the indications for HA brain irradiation.
Providing of hippocampal sparing techniques is difficult
and expensive. Thus, responsible decision must be made
with respect to selection of appropriate patients espe-
cially in terms of probability of long term survival and
QoL. The difference in the cost of basic 3D-CRT and
advanced radiotherapeutic methods needed for HA brain
irradiation is probably the most important controversy.
Unfortunately, in many departments, especially in low-
income countries, IMRT techniques are not widely avail-
able even for curative treatment (head and neck or prostate
cancer). And even in large centers, it is not clear, whether
implementation of more expensive RT technique is worth-
while to prevent probable mild neurocognitive decline.
Only well designed randomized trials and cost-effective
analysis can evaluate whether, or not these approaches
should be incorporated into general practice. On the othertocol IMRT treatment planning according to RTOG 0933
Variation acceptable Unacceptable deviation
s to MRI/CT
ted






> 2 and≤ 7 mm deviation
using the Hausdorff distance*
> 7 mm using the
Hausdorff distance*
D2% > 37.5 Gy≤ 40 Gy V30 < 90%
D98% < 25 Gy D2% > 40 Gy
D100%≤ 10 Gy D100% > 10 Gy
Dmax≤ 17 Gy Dmax > 17 Gy
y Dmax≤ 37.5 Gy Dmax > 37.5 Gy
1–3 break days > 3 break days
; D100%: dose in 100% of volume; Dmax: maximal dose; V30: volume irradiated by
Figure 2 Examples of non-coplanar Arc treatment plan with hippocampal sparing and homogenous dose coverage in the rest of
the brain.
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campus can be considered as other OAR assuming that
no other standard OAR will receive more radiation.
Especially for patients with PCI or for children, it is im-
portant consider potential AE of some techniques using
for hippocampal sparing such as helical tomotherapy for
example. In an effort to minimize dose in hippocampus,
there is a risk of overtreatment of other parts of the brain
and surrounding structures with increased risk of induced
secondary malignancies. To assess this potential disadvan-
tage of helical tomotherapy, one study measured integral
doses in uninvolved brain regions of HGG patients for
both conventional IMRT and helical tomotherapy tech-
niques [57]. The results proved reduction of brain inte-
gral dose in average by 23% after IMRT compared with
tomotherapy in all tested treatment plans. Despite a theor-
etical risk of local overtreatment, integral dose delivered
by any technique has been surprisingly lower in sparing
plans compared with non-sparing ones. From this
point of view, usage of traditional IMRT techniques is
considered as optimal way how to spare hippocampus.Figure 3 Simple RT technique using 2 laterolateral brain fields with 2Another approach reducing brain integral dose would be
the proton therapy [58].
Considering sparing of some part of brain during
WBRT in BM treatment as well as in prophylactic situ-
ation, a worry of subsequent increase risk of intracranial
disease progression in spared regions is justified. However,
many imaging studies described overall low number of
metastases in the hippocampus as well as in other parts of
the limbic circuit [59-62]. For example, on study evaluated
697 BM in 107 patients, only one of 53 oligometastatic
patients (1.9%) had hippocampal metastases (that is 0.97%
of all their metastases). In the group of non-oligometa-
static patients, in hippocampus was presented only 2.29%
of BM [59]. Moreover, other study with 371 patients
and 1133 BM localize 8.6% of them into the HA region
(hippocampus plus 5 mm margin); however, no metastasis
was presented in the hippocampus itself [60]. It can be
concluded, that sparing of hippocampus would likely not
significantly increase the risk of treatment failure.
On the other hand, others have hypothesized, that
neurogenic niches may not only harbor normal NSC butleafs positioned to block the hippocampus.
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a retrospective analysis of dose coverage of neurogenic
niches in patients with malignant gliomas performed
by Evers et al., dose to subventricular zone greater than
43 Gy was associated with a significant improvement in
progression free survival compared to those with lower
dose (15.0 vs. 7.2 months PFS; P = 0.028) [63]. Interest-
ingly, similar analysis of dose delivered to the hippo-
campal formation did not yield statistically significant
results which confirm the complexity of radiation effects
on neurogenic niches [63]. These results highlight the
need for well-designed clinical trials as well as contin-
ued pre-clinical research to evaluate beneficial or detri-
mental effects of hippocampal sparing.
The most important treatment related controversy is
inconsistency in recommended dose reduction. At this
time there is no level I evidence to conclusively support
a particular recommendation. Preclinical studies indicate
probable no-shoulder dose–response [29]. On the other
hand, retrospective clinical studies suggest that biological
equivalent dose greater than 7.3 Gy EQD2 applied to 40%
of hippocampus was associated with worse NCF outcomes
[43]. Ongoing phase III trials evaluating NCF function will
provide more possible dose-volume constraints associated
with possible milder NCF impairment. Because of cost
of advanced radiotherapy techniques, it is controversial
whether apply intensity modulated plan in some particular
patients which will be not able to achieve assumed dose
goals especially in situation of standard three dimensional
conformal plan would be originally considered. Based on
the recently reported phase II trial [11], a dosimetric
recommendation for HA WBRT (Dmedian < 7.8 Gy,
D100% < 10 Gy and Dmax < 15.3 Gy) can be recom-
mended for patients with brain metastasis and expected
survival greater than 6 months.
Future directions
Although HA appears to be promising in reducing cog-
nitive affects after RT, ongoing studies and other clinical
research are needed to determine the optimal dose and
volume constraints. It is not clear based on radiobiology
of neural stem cell response to radiation whether it is
possible to define specific threshold values in terms of
recommended target doses. Even if the nature of radi-
ation injury of hippocampus is same in all patients, the
different target doses that can reasonably be achieved in
different clinical situations vary with prescribed doses
and different clinical target volumes i.e. partial vs. whole
brain irradiation or in therapeutic vs. prophylactic indi-
cation or in adults vs. children brain tumors. The role of
HA in PCI and children has also not been established
and is an area of future investigation. Optimal NCF
evaluation tools to measure specific effects on hippocam-
pus, as opposed to other etiologies of cognitive dysfunction,and optimal timing of administration is still largely un-
known. To be able to compare results from different stud-
ies it is necessary to standardize process of NCF testing.
However, the ideal tools to measure early changes in cog-
nitive function as compared to late effects of treatment
may not be the same. In addition, the testing must be feas-
ible to administer in a busy clinical practice. Ongoing re-
search on pathophysiology of brain irradiation injury may
reveal other possible important brain structures whose
sparing can contribute to better preservation of NCF, or
further analysis of hippocampal subregion (cornu ammo-
nis for example) may demonstrate avoidance region with
higher priority for dose sparing. Development of cost-
effectiveness analysis will be probably one of the most im-
portant steps forward to implementation of this advanced
radiotherapy technique especially in low and middle in-
come countries. Comparing cost of standard 3D-CRT
(classical 2 latero-lateral fields for WBRT for example) and
cost of VMAT or helical tomotherapy systems for example
poses important questions whether consequent increase
in costs offset theoretical mitigation of neurocognitive
decline related to brain irradiation. Especially in situation
where are presented many other different sources of cog-
nition impairment in patients suffering from advanced
cancer.
Conclusion
In summary, it is now technically and dosimetrically
feasible to implement HA approaches into clinical prac-
tice. Furthermore, taking into account very low beam-on
time of modern RT systems, it is ethically justifiable to
use these techniques also in the palliative indications for
patients with BM as well as HGG. As regards boosting
of BM, comprehensive techniques with SIB provide tumor
doses comparable with sequential approach of classical
WBRT + SRS which require even 2 planning procedures
which can result in such dosimetric inaccuracies. More-
over, HA WBRT with SIB provides better hippocampal
sparing and this treatment approach seems to be the most
promising to implement into clinical practice after con-
firmation of better cognitive outcomes after sparing of
hippocampus in ongoing clinical trials.
Recently, first phase II clinical trial with prospectively
measured NCF while providing HA WBRT showed sig-
nificantly better outcomes for patients treated with hip-
pocampal sparing in terms of better cognitive functions as
well as quality of life. Conventional techniques of WBRT
are now still recommended as standard approach for
patients with multiple brain metastases and hippocampal
sparing is generally not used outside of the context of clin-
ical trials. Phase III studies are now ongoing and further
implementation will depend on the results of these trials.
For treatment of PBT, especially in its hemispherical loca-
tion, it is reasonable to include contralateral hippocampus
Kazda et al. Radiation Oncology 2014, 9:139 Page 9 of 10
http://www.ro-journal.com/content/9/1/139into the OARs assuming that no other organ at risks or
target volumes would be over/under irradiated. Ongoing
phase III trials will definitely prove the clinical significance
of this developing approach.
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